Compare Kohl's Corporation (KSS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Kohl's Corporation trades at $20.36 (market cap $2.28B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.4× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.49% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KSS | XBI | |
|---|---|---|
Market Cap | $2.28B | $10.11B |
Volume | 4,960,280 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $24.71 | $169.55 |
52-Week Low | $11.72 | $104.99 |
Typical Hold Time | 48 Days | 38 Days |
Enterprise Value | $7.88B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.35, up 1.14% with a bullish technical outlook despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. Recent Q2 2026 earnings beat expectations with $1.28 EPS versus $0.58 expected, and the company raised full-year guidance amid merchandising improvements.
KSS presents a value opportunity with strong fundamentals but faces headwinds from 18 consecutive quarters of declining sales. Analyst consensus is mixed with 30% buy ratings and a $15.50 price target below current levels. The turnaround story depends on holiday execution and sales stabilization to sustain recent gains beyond tariff-related benefits.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
